



MEMPHASYS
REPRODUCTIVE BIOTECHNOLOGY

ASX Release
ASX Code: MEM

4 September 2026

Investor Webinar Invite

Memphasys Limited (ASX: MEM) ("Memphasys" or "the Company") is pleased to invite shareholders to attend an upcoming investor webinar, Lynx Discovery Series: Health Innovation.

The webinar will be held on Tuesday, 8 September 2026 at 12:00pm AEST.

Register via: https://us02web.zoom.us/webinar/register/WN_2ih3cNIDQtup7uBl-szWTA#/registration

Memphasys Non-Executive Director and Chair of the Commercialisation Committee, Marjan Mikel, will present an update on the Company and the commercialisation of its Felix™ System, a rapid, automated sperm separation device designed for use in assisted reproductive technology (ART), including IVF procedures.

The presentation will focus on Memphasys' recent progress in the global commercialisation of the Felix™ System following the achievement of key regulatory clearances. Mr Mikel will discuss recent developments announced by the Company, including new market registrations, distribution and supply agreements, initial and repeat cartridge orders, and the growing deployment of Felix™ across fertility clinics in Australia and international markets.

Following the presentation, Mr Mikel will participate in a moderated Q&A session, providing investors with the opportunity to put questions directly to management.

Investors are encouraged to register in advance using the link above. Questions can be submitted during the webinar through the Q&A function.

A recording of the webinar will be made available following the event.

Authorised by the Board of Memphasys Limited.

Ends

For further information, please contact:

Colin Jacoby
Chapter One Advisors
Tel: +61 439 980 359
E: cjacoby@chapteroneadvisors.com.au

Memphasys Limited
Level 1, 34-36 Richmond Road
Homebush West, NSW 2140

Contact Details
P +612 8415 7300

E info@memphasys.com
W memphasys.com
ABN 33 120 047 556

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio-separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a repeatable alternative.

Memphasys' commercial strategy focuses on building contracted sales through direct and distribution-led channels, scaling production to improve margins, and establishing Felix™ as a global standard in sperm preparation for ART procedures.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These statements are based on Memphasys' current expectations, estimates, projections, beliefs and assumptions and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control. Actual results may differ materially from those expressed or implied. Memphasys cautions shareholders and prospective shareholders not to place undue reliance on forward-looking statements, which speak only as at the date of this announcement. Except as required by law or an applicable regulatory authority, Memphasys undertakes no obligation to publicly revise or update those statements.